Ixiaro market seen expanding as Japanese encephalitis cases and travel demand rise

The Business Research Company says the global Ixiaro vaccine market is set for steady growth through 2035, driven by Japanese encephalitis cases, travel medicine demand and broader vaccination efforts. North America is projected to lead the market in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - Ixiaro is used to prevent Japanese encephalitis, a mosquito-borne disease that can cause severe brain inflammation and death. - Rising infection risk, travel demand and public health vaccination programs are expanding the market’s commercial and public-health relevance. - The report frames Ixiaro as part of a broader shift toward prevention in endemic regions and among international travelers.

What happened: - The Business Research Company released its Global Market Report 2026 on the Ixiaro market, covering market size, trends and forecasts for 2026-2035. - The report says the market is being shaped by repeated Japanese encephalitis outbreaks, increased international travel and government-led immunization efforts. - The company also highlights a free sample of the report and the full report for readers seeking more detail: Free sample and the full report.

The details: - Ixiaro is an inactivated Japanese encephalitis vaccine recommended mainly for travelers visiting areas where the disease is common. - The vaccine is typically given in two doses spaced 28 days apart. - The report says historical market growth was supported by public health vaccination campaigns, proven effectiveness of inactivated vaccines and immunization programs led by governments. - Future growth is expected to come from more travel medicine clinics, broader vaccination coverage across Asia-Pacific, greater awareness of vector-borne diseases, stronger cold-chain infrastructure and more public health funding. - The report points to growing demand for travel vaccinations, expanded mosquito-borne disease prevention programs, routine immunization schedules, protection in endemic regions and broader use of inactivated virus vaccines. - The report says Japanese encephalitis prevalence is a major demand driver because the disease is spread by mosquitoes and is linked to intensified rice farming, population growth and expanded pig farming in endemic areas. - In August 2024, the World Health Organization estimated about 100,000 clinical cases of Japanese encephalitis each year worldwide and about 25,000 deaths. - Clinical research activity is another driver, with ClinicalTrials.gov reporting 39,710 new studies in 2023, bringing the total to 477,203 by year-end. - Personalized medicine is also expected to support market growth as vaccination strategies become more tailored to geography, exposure and patient health status. - In February 2024, the Personalized Medicine Coalition said the FDA approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022.

Between the lines: - The report suggests the Ixiaro market is tied to two trends at once: disease prevention in high-risk regions and preventive care for travelers. - Asia-Pacific’s expected growth reflects where Japanese encephalitis risk is most concentrated, while North America’s lead likely reflects travel medicine demand and purchasing power. - The report’s focus on clinical trials and personalized medicine signals a broader vaccine market that is becoming more data-driven and more targeted.

What's next: - North America is projected to hold the largest share of the Ixiaro market in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa, pointing to a globally distributed opportunity set for vaccine makers and distributors. - The 2026 edition adds market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards, hotspot infographics and updated graphics and tables.

The bottom line: - Ixiaro’s growth story is being driven less by a single product cycle and more by persistent disease risk, travel demand and broader prevention programs across global markets.